FDA said it is partnering with the European Medicines Agency (EMA) on regulatory strategies to facilitate the development of COVID-19 vaccines.

During a March 18 meeting, regulators discussed necessary preclinical data and the need to evaluate theoretical risk for vaccine-induced disease enhancement, while acknowledging the urgency of proceeding to human clinical trials with SARS-CoV-2 candidate vaccines

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…